1. Centers for Disease Control National Diabetes Fact Sheet. General information and national estimates on diabetes in the United States. In, Atlanta: Centers for Disease Control and Prevention, US Dept of Health and Human Services, 2007
2. Hogan P, Dall T, Nikolov P: Economic costs of diabetes in the US in 2002. Diabetes Care 26:917, 2003
3. Narayan KM et al: Lifetime risk for diabetes mellitus in the United States. Jama 290:1884, 2003
4. Holman RR et al: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577, 2008
5. Skyler JS et al: Intensive glycemic control and the prevention of cardiovascular events: Implications of the ACCORD, ADVANCE, and
VA diabetes trials: A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association.
Diabetes Care 32:187, 2009
6. Beisswenger PJ, Moore LL, Curphey TJ: Relationship between glycemic control and collagen-linked advanced glycosylation end products in type I diabetes. Diabetes Care 16:689, 1993
7. Dyer DG et al: Accumulation of Maillard reaction products in skin
collagen in diabetes and aging.
J Clin Invest 91:2463, 1993
8. Buckingham BA et al: Scleroderma-like changes in insulin-dependent diabetes mellitus: Clinical and biochemical studies. Diabetes Care 7:163, 1984
9. Monnier VM et al: Skin
collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: Relevance of glycated
collagen products versus HbA1c as markers of diabetic complications. DCCT Skin
Collagen Ancillary Study Group. Diabetes Control and Complications Trial.
Diabetes 48:870, 1999
10. Olerud JE: Ellenburg & Rifkin's Diabetes Mellitus. New York, McGraw-Hill, 895-908, 2003
11. Joshi N et al: Infections in patients with diabetes mellitus. N Engl J Med 341:1906, 1999
12. Cruz PD Jr, Hud JA Jr: Excess
insulin binding to insulin-like growth factor receptors: Proposed mechanism for acanthosis nigricans.
J Invest Dermatol 98:82S, 1992
13. Brunzell JD, Porte D Jr, Bierman EL: Abnormal lipoprotein-lipase-mediated plasma triglyceride removal in untreated diabetes mellitus associated with hypertriglyceridemia. Metabolism 28:901, 1979
14. Ansel JC et al: Interactions of the skin and nervous system. J Investig Dermatol Symp Proc 2:23, 1997
15. Reiber GE, Pecoraro RE, Koepsell TD: Risk factors for amputation in patients with diabetes mellitus. A case-control study. Ann Intern Med 117:97, 1992
16. Schwartz RA: Acanthosis nigricans. J Am Acad Dermatol 31:1, 1994
17. Stuart CA, Pate CJ, Peters EJ: Prevalence of acanthosis nigricans in an unselected population. Am J Med 87:269, 1989
18. Tasjian D, Jarratt M: Familial acanthosis nigricans. Arch Dermatol 120:1351, 1984
19. Stuart CA et al: Acanthosis nigricans as a risk factor for non-insulin dependent diabetes mellitus. Clin Pediatr (Phila) 37:73, 1998
20. Andreev V: Malignant acanthosis nigricans. Seminars in Dermatology 3:265, 1984
21. Dunaif A:
Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis.
Endocr Rev 18:774, 1997
22. Torley D, Bellus GA, Munro CS: Genes, growth factors and acanthosis nigricans. Br J Dermatol 147:1096, 2002
23. Flier JS, Usher P, Moses
AC: Monoclonal antibody to the type I insulin-like growth factor (IGF-I) receptor blocks IGF-I receptor-mediated DNA synthesis: clarification of the mitogenic mechanisms of IGF-I and
insulin in human skin fibroblasts.
Proc Natl Acad Sci U S A 83:664, 1986
24. Ellis DL et al: Melanoma, growth factors, acanthosis nigricans, the sign of Leser-Trelat, and multiple acrochordons. A possible role for alpha-transforming growth factor in cutaneous paraneoplastic syndromes. N Engl J Med 317:1582, 1987
25. Koyama S et al: Transforming growth factor-alpha (TGF alpha)-producing gastric carcinoma with acanthosis nigricans: an endocrine effect of TGF alpha in the pathogenesis of cutaneous paraneoplastic syndrome and epithelial hyperplasia of the esophagus. J Gastroenterol 32:71, 1997
26. Brown J, Winkelmann RK: Acanthosis nigricans: a study of 90 cases. Medicine (Baltimore) 47:33, 1968
27. Lever's histopathology of the skin. 8th edition. Philadelphia: Lippincott Williams and Wilkins, 393-396, 1997
28. Bohm M, Luger TA, Metze D: Treatment of mixed-type acanthosis nigricans with topical calcipotriol. Br J Dermatol 139:932, 1998
29. Blobstein SH: Topical therapy with
tretinoin and ammonium lactate for acanthosis nigricans associated with obesity.
Cutis 71:33, 2003
30. Coates P, Shuttleworth D, Rees A: Resolution of nicotinic acid-induced acanthosis nigricans by substitution of an analogue (acipimox) in a patient with type V hyperlipidaemia. Br J Dermatol 126:412, 1992
31. Kebria MM et al: Malignant acanthosis nigricans, tripe palms and the sign of Leser-Tre'lat, a hint to the diagnosis of early stage ovarian cancer: A case report and review of the literature. Gynecol Oncol 101:353, 2006
32. Frost D, Beischer W: Limited joint mobility in type 1 diabetic patients: Associations with microangiopathy and subclinical macroangiopathy are different in men and women. Diabetes Care 24:95, 2001
33. Silverstein JH et al: Long-term glycemic control influences the onset of limited joint mobility in type 1 diabetes. J Pediatr 132:944, 1998
34. Rosenbloom AL et al: Limited joint mobility in childhood diabetes mellitus indicates increased risk for microvascular disease. N Engl J Med 305:191, 1981
35. Infante JR et al: Changes in frequency and severity of limited joint mobility in children with type 1 diabetes mellitus between 1976–78 and 1998. J Pediatr 138:33, 2001
36. Buckingham B et al: Skin, joint, and pulmonary changes in type I diabetes mellitus. Am J Dis Child 140:420, 1986
37. Fleischmajer R, Faludi G, Krol S: Scleredema and diabetes mellitus. Arch Dermatol 101:21, 1970
38. Cohn BA, Wheeler CE Jr, Briggaman RA: Scleredema adultorum of Buschke and diabetes mellitus. Arch Dermatol 101:27, 1970
39. Cole GW, Headley J, Skowsky R: Scleredema diabeticorum: A common and distinct cutaneous manifestation of diabetes mellitus. Diabetes Care 6:189, 1983
40. Sattar MA et al: Scleroedema diabeticorum: A minor but often unrecognized complication of diabetes mellitus. Diabet Med 5:465, 1988
41. Varga J et al: Scleredema adultorum: Case report and demonstration of abnormal expression of extracellular matrix genes in skin fibroblasts in vivo and in vitro. Br J Dermatol 132:992, 1995
42. Seyger MM et al: A patient with a severe scleroedema diabeticorum, partially responding to low-dose
methotrexate.
Dermatology 198:177, 1999
43. Lee MW et al: Electron beam therapy in patients with scleredema. Acta Derm Venereol 80:307, 2000
44. Parker F et al: Evidence for the chylomicron origin of lipids accumulating in diabetic eruptive xanthomas: A correlative lipid biochemical, histochemical, and electron microscopic study. J Clin Invest 49:2172, 1970
45. Bagdade JD, Porte D Jr, Bierman EL: Diabetic lipemia. A form of acquired fat-induced lipemia. N Engl J Med 276:427, 1967
46. Chait A, Robertson HT, Brunzell JD: Chylomicronemia syndrome in diabetes mellitus. Diabetes Care 4:343, 1981
47. Parker F: Xanthomas and hyperlipidemias. J Am Acad Dermatol 13:1, 1985
48. Valerius NH et al: Neutrophil and lymphocyte function in patients with diabetes mellitus. Acta Med Scand 211:463, 1982
49. Gallacher SJ et al: Neutrophil bactericidal function in diabetes mellitus: Evidence for association with blood glucose control. Diabet Med 12:916, 1995
50. Singh N, Armstrong DG, Lipsky BA: Preventing foot ulcers in patients with diabetes. Jama 293:217, 2005
51. Pecoraro RE, Reiber GE, Burgess EM: Pathways to diabetic limb amputation. Basis for prevention. Diabetes Care 13:513, 1990
52. Consensus Development Conference on Diabetic Foot Wound Care: 7–8 April 1999, Boston, Massachusetts. American Diabetes Association. Diabetes Care 22:1354-1360, 1999
53. Ramsey SD et al: Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care 22:382, 1999
54. Levy DM et al: Depletion of cutaneous nerves and neuropeptides in diabetes mellitus: An immunocytochemical study. Diabetologia 32:427, 1989
55. Antezana M et al: Neutral endopeptidase activity is increased in the skin of subjects with diabetic ulcers. J Invest Dermatol 119:1400, 2002
56. Apelqvist J, Larsson J, Agardh CD: The influence of external precipitating factors and peripheral neuropathy on the development and outcome of diabetic foot ulcers. J Diabet Complications 4:21, 1990
57. Soulier SM: The use of running shoes in the prevention of plantar diabetic ulcers. J Am Podiatr Med Assoc 76:395, 1986
58. Boyko EJ et al: Prediction of diabetic foot ulcer occurrence using commonly available clinical information: The Seattle Diabetic Foot Study. Diabetes Care 29:1202, 2006
59. Wieman TJ, Smiell JM, Su Y: Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (
becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study.
Diabetes Care 21:822, 1998
60. Edmonds M et al: New treatments in ulcer healing and wound infection. Diabetes Metab Res Rev 16(Suppl 1):S51, 2000
61. Langer A, Rogowski W: Systematic review of economic evaluations of human cell-derived wound care products for the treatment of venous leg and diabetic foot ulcers. BMC Health Serv Res 9:115, 2009
62. Van Gils CC et al: Amputation prevention by vascular surgery and podiatry collaboration in high-risk diabetic and nondiabetic patients. The Operation Desert Foot experience. Diabetes Care 22:678, 1999
63. Muller SA, Winkelmann RK: Necrobiosis lipoidica diabeticorum. A clinical and pathological investigation of 171 cases. Arch Dermatol 93:272, 1966
64. O'Toole EA et al: Necrobiosis lipoidica: Only a minority of patients have diabetes mellitus. Br J Dermatol 140:283, 1999
65. Lowitt MH, Dover JS: Necrobiosis lipoidica. J Am Acad Dermatol 25:735, 1991
66. Dandona P et al: Glycosylated haemoglobin in patients with necrobiosis lipoidica and granuloma annulare. Clin Exp Dermatol 6:299, 1981
67. Mann RJ, Harman RR: Cutaneous anaesthesia in necrobiosis lipoidica. Br J Dermatol 110:323, 1984
68. Imtiaz KE, Khaleeli AA: Squamous cell carcinoma developing in necrobiosis lipoidica. Diabet Med 18:325, 2001
69. Crosby DL, Woodley DT, Leonard DD: Concomitant granuloma annulare and necrobiosis lipoidica. Report of a case and review of the literature. Dermatologica 183:225, 1991
70. Petzelbauer P, Wolff K, Tappeiner G: Necrobiosis lipoidica: Treatment with systemic corticosteroids. Br J Dermatol 126:542, 1992
71. Kreuter A et al: Fumaric acid esters in necrobiosis lipoidica: Results of a prospective noncontrolled study. Br J Dermatol 153:802, 2005
72. Darvay A, Acland KM, Russell-Jones R: Persistent ulcerated necrobiosis lipoidica responding to treatment with cyclosporin. Br J Dermatol 141:725, 1999
73. Dubin BJ, Kaplan EN: The surgical treatment of necrobiosis lipoidica diabeticorum. Plast Reconstr Surg 60:421, 1977
74. Dabski K, Winkelmann RK: Generalized granuloma annulare: Clinical and laboratory findings in 100 patients. J Am Acad Dermatol 20:39, 1989
75. Veraldi S et al: Laboratory abnormalities in granuloma annulare: A case-control study. Br J Dermatol 136:652, 1997
76. Melin H: An atrophic circumscribed skin lesion in the lower extremities of diabetics. Acta Med Scand 176:(Suppl 423):1, 1964
77. Binkley GW: Dermopathy in diabetes mellitus. Arch Dermatol 92:106, 1965
78. Borssen B, Bergenheim T, Lithner F: The epidemiology of foot lesions in diabetic patients aged 15–50 years. Diabet Med 7:438, 1990
79. Danowski TS et al: Shin spots and diabetes mellitus. Am J Med Sci 251:570, 1966
80. Lithner F: Cutaneous reactions of the extremities of diabetics to local thermal trauma. Acta Med Scand 198:319, 1975
81. Shemer A et al: Diabetic dermopathy and internal complications in diabetes mellitus. Int J Dermatol 37:113, 1998
82. Rapini RP et al: Acquired perforating dermatosis. Evidence for combined transepidermal elimination of both
collagen and elastic fibers.
Arch Dermatol 125:1074, 1989
83. Faver IR, Daoud MS, Su WP: Acquired reactive perforating collagenosis. Report of six cases and review of the literature. J Am Acad Dermatol 30:575, 1994
84. Bernstein JE et al: Reduced threshold to suction-induced blister formation in insulin-dependent diabetics. J Am Acad Dermatol 8:790, 1983
85. Toonstra J: Bullosis diabeticorum. Report of a case with a review of the literature. J Am Acad Dermatol 13:799, 1985
86. Ogden CL et al: Prevalence of overweight and obesity in the United States, 1999–2004. Jama 295:1549, 2006
87. Kelesidis T et al: Narrative review: The role of leptin in human physiology: Emerging clinical applications. Ann Intern Med 152:93, 2010
88. Oral EA et al: Leptin-replacement therapy for lipodystrophy. N Engl J Med 346:570, 2002
89. Lee JH et al: Recombinant methionyl human leptin therapy in replacement doses improves
insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy.
J Clin Endocrinol Metab 91:2605, 2006
90. Schaffer JV, Bolognia JL: The melanocortin-1 receptor: Red hair and beyond. Arch Dermatol 137:1477, 2001
91. Krude H et al: Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 19:155, 1998
92. Katsuki A et al: Plasma levels of agouti-related protein are increased in obese men. J Clin Endocrinol Metab 86:1921, 2001
93. Sonnett TE et al: Diabetes mellitus, inflammation, obesity: Proposed treatment pathways for current and future therapies. Ann Pharmacother 44:701, 2010
94. Inui A et al: Ghrelin, appetite, and gastric motility: The emerging role of the stomach as an endocrine organ. Faseb J 18:439, 2004
95. Loffler H, Aramaki JU, Effendy I: The influence of body mass index on skin susceptibility to sodium lauryl sulphate. Skin Res Technol 8:19, 2002
96. Guida B et al: The impact of obesity on skin disease and epidermal permeability barrier status. J Eur Acad Dermatol Venereol 24:191, 2010
97. Yosipovitch G et al: Skin surface pH in intertriginous areas in NIDDM patients. Possible correlation to candidal intertrigo. Diabetes Care 16:560, 1993
98. Enser M, Avery NC: Mechanical and chemical properties of the skin and its
collagen from lean and obese-hyperglycaemic (ob/ob) mice.
Diabetologia 27:44, 1984
99. de Jongh RT et al: Impaired local microvascular vasodilatory effects of
insulin and reduced skin microvascular vasomotion in obese women.
Microvasc Res 75:256, 2008
100. Yosipovitch G, DeVore A, Dawn A: Obesity and the skin: Skin physiology and skin manifestations of obesity. J Am Acad Dermatol 56:901, 2007
101. Scheinfeld NS: Obesity and dermatology. Clin Dermatol 22:303, 2004
102. Klein S et al: Absence of an effect of liposuction on
insulin action and risk factors for coronary heart disease.
N Engl J Med 350:2549, 2004
103. Mohammed BS et al: Long-term effects of large-volume liposuction on metabolic risk factors for coronary heart disease.
Obesity (Silver Spring) 16:2648, 2008
104. Hollowell JG et al: Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 87:489, 2002
105. Weetman AP: Graves' disease. N Engl J Med 343:1236, 2000
106. Laurberg P et al: High incidence of multinodular toxic goitre in the elderly population in a low
iodine intake area vs. high incidence of Graves' disease in the young in a high
iodine intake area: Comparative surveys of thyrotoxicosis epidemiology in East-Jutland Denmark and Iceland.
J Intern Med 229:415, 1991
107. Buyukgebiz A: Congenital hypothyroidism clinical aspects and late consequences. Pediatr Endocrinol Rev 1(Suppl 2):185, 2003
108. Polak M: Hyperthyroidism in early infancy: Pathogenesis, clinical features and diagnosis with a focus on neonatal hyperthyroidism. Thyroid 8:1171, 1998
109. Brent GA: The molecular basis of thyroid hormone action. N Engl J Med 331:847, 1994
110. Rees Smith B, McLachlan SM, Furmaniak J: Autoantibodies to the thyrotropin receptor. Endocr Rev 9:106, 1988
111. Surks MI, Sievert R: Drugs and thyroid function. N Engl J Med 333:1688, 1995
112. Prabhakar BS, Bahn RS, Smith TJ: Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. Endocr Rev 24:802, 2003
113. Derwahl M et al: Pathogenesis of toxic thyroid adenomas and nodules: Relevance of activating mutations in the TSH-receptor and Gs-alpha gene, the possible role of
iodine deficiency and secondary and TSH-independent molecular mechanisms.
Exp Clin Endocrinol Diabetes 106(Suppl 4):S6, 1998
114. Safer JD, Crawford TM, Holick MF: Topical thyroid hormone accelerates wound healing in mice. Endocrinology 146:4425, 2005
115. Sherman SI et al: Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med 340:1075, 1999
116. Ai J, Leonhardt JM, Heymann WR: Autoimmune thyroid diseases: Etiology, pathogenesis, and dermatologic manifestations. J Am Acad Dermatol 48:641, 2003
117. Fatourechi V, Pajouhi M, Fransway AF: Dermopathy of Graves disease (pretibial myxedema). Review of 150 cases. Medicine (Baltimore) 73:1, 1994
118. Parker LN et al: The early diagnosis of atypical thyroid acropachy. Arch Intern Med 142:1749, 1982
119. Fatourechi V, Ahmed DD, Schwartz KM: Thyroid acropachy: Report of 40 patients treated at a single institution in a 26-year period. J Clin Endocrinol Metab 87:5435, 2002
120. Dreskin SC, Andrews KY: The thyroid and urticaria. Curr Opin Allergy Clin Immunol 5:408, 2005
121. Biro E et al: Association of systemic and thyroid autoimmune diseases. Clin Rheumatol 25:240, 2006
122. Callen JP, McCall MW: Bullous pemphigoid and Hashimoto's thyroiditis. J Am Acad Dermatol 5:558, 1981
123. Coleman R, Hay RJ: Chronic mucocutaneous candidosis associated with hypothyroidism: A distinct syndrome? Br J Dermatol 136:24, 1997
124. Puavilai S et al: Prevalence of thyroid diseases in patients with alopecia areata. Int J Dermatol 33:632, 1994
125. Zettinig G et al: Dermatitis herpetiformis is associated with atrophic but not with goitrous variant of Hashimoto's thyroiditis. Eur J Clin Invest 30:53, 2000
126. Schwartz KM et al: Dermopathy of Graves' disease (pretibial myxedema): Long-term outcome. J Clin Endocrinol Metab 87:438, 2002
127. Pingsmann A, Ockenfels HM, Patsalis T: Surgical excision of pseudotumorous pretibial myxedema. Foot Ankle Int 17:107, 1996
128. Wermers RA et al: Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993–2001: An update on the changing epidemiology of the disease. J Bone Miner Res 21:171, 2006
129. Foley J et al: PTHrP regulates epidermal differentiation in adult mice. J Invest Dermatol 111:1122, 1998
130. Sharpe GR et al: Human keratinocytes express transcripts for three isoforms of parathyroid hormone-related protein (PTHrP), but not for the parathyroid hormone/PTHrP receptor: Effects of 1,25(OH)2 vitamin D3. Br J Dermatol 138:944, 1998
131. Lowik CW et al: Regulation of parathyroid hormonelike protein production in cultured normal and malignant keratinocytes. J Invest Dermatol 98:198, 1992
132. Atillasoy EJ, Burtis WJ, Milstone LM: Immunohistochemical localization of parathyroid hormone-related protein (PTHRP) in normal human skin. J Invest Dermatol 96:277, 1991
133. Blomme EA et al: Spatial and temporal expression of parathyroid hormone-related protein during wound healing. J Invest Dermatol 112:788, 1999
134. Danks JA et al: Parathyroid hormone-related protein: Immunohistochemical localization in cancers and in normal skin. J Bone Miner Res 4:273, 1989
135. Walsh JS, Fairley JA: Calcifying disorders of the skin. J Am Acad Dermatol 33:693, 1995
136. Dagher HN, Aboujaoude ZC, Jabbour SA: Chronic urticaria: An unusual initial manifestation of primary hyperparathyroidism. Endocr Pract 8:47, 2002
137. Heppner C et al: Somatic mutation of the MEN1 gene in parathyroid tumours. Nat Genet 16:375, 1997
138. Basile C et al: Hyperbaric
oxygen therapy for calcific uremic arteriolopathy: A case series.
J Nephrol 15:676, 2002
139. Podymow T, Wherrett C, Burns KD: Hyperbaric
oxygen in the treatment of calciphylaxis: A case series.
Nephrol Dial Transplant 16:2176, 2001
140. Schlieper G et al: Sodium thiosulfate in the treatment of calcific uremic arteriolopathy. Nat Rev Nephrol 5:539, 2009
141. Lee Y et al: Hypocalcaemia-induced pustular psoriasis-like skin eruption. Br J Dermatol 152:591, 2005
142. Makitie O et al: Bone health in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED): Findings in 25 adults. Clin Endocrinol (Oxf) 64:489, 2006
143. Wilson LC, Hall CM: Albright's hereditary osteodystrophy and pseudohypoparathyroidism. Semin Musculoskelet Radiol 6:273, 2002
144. Beauregard C, Dickstein G, Lacroix A: Classic and recent etiologies of Cushing's syndrome: Diagnosis and therapy. Treat Endocrinol 1:79, 2002
145. Ilias I et al: Cushing's syndrome due to ectopic
corticotropin secretion: Twenty years' experience at the National Institutes of Health.
J Clin Endocrinol Metab 90:4955, 2005
146. Kirk JM et al: Cushing's syndrome caused by nodular adrenal hyperplasia in children with McCune-Albright syndrome. J Pediatr 134:789, 1999
147. Groussin L et al: Adrenal pathophysiology: Lessons from the Carney complex. Horm Res 64:132, 2005
148. Orth DN: Cushing's syndrome. N Engl J Med 332:791, 1995
149. Becker KL: Principles and Practice of Endocrinology and Metabolism. Philadelphia: Lippincott Williams and Wilkins, 726-729, 2001
150. Cohen KL, Noth RH, Pechinski T: Incidence of pituitary tumors following adrenalectomy. A long-term follow-up study of patients treated for Cushing's disease. Arch Intern Med 138:575, 1978
151. Ten S, New M, Maclaren N: Clinical review 130: Addison's disease 2001. J Clin Endocrinol Metab 86:2909, 2001
152. Alevritis EM et al: Infectious causes of adrenal insufficiency. South Med J 96:888, 2003
153. Zelissen PM, Bast EJ, Croughs RJ: Associated autoimmunity in Addison's disease. J Autoimmun 8:121, 1995
154. Barkan A, Glantz I: Calcification of auricular cartilages in patients with hypopituitarism. J Clin Endocrinol Metab 55:354, 1982
155. Bensyl DM et al: Contraceptive use–United States and territories, Behavioral Risk Factor Surveillance System, 2002. MMWR Surveill Summ 54:1, 2005
156. Farage MA, Berardesca E, Maibach H: The possible relevance of sex hormones on irritant and allergic responses: Their importance for skin testing. Contact Dermatitis 62:67, 2010
157. Hall G, Phillips TJ: Estrogen and skin: the effects of estrogen, menopause, and hormone replacement therapy on the skin. J Am Acad Dermatol 53:555, 2005
158. Sarkar R et al: Melasma in men: A clinical, aetiological and histological study. J Eur Acad Dermatol Venereol 24: 768-772, 2009
159. Shelley WB et al: Estrogen dermatitis. J Am Acad Dermatol 32:25, 1995
160. Rendon M et al: Treatment of melasma. J Am Acad Dermatol 54:S272, 2006
161. Petri M et al: Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 353:2550, 2005
162. Buyon JP et al: The effect of combined estrogen and
progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: A randomized trial.
Ann Intern Med 142:953, 2005
163. Lee H: CYP21 mutations and congenital adrenal hyperplasia. Clin Genet 59:293, 2001
164. Chen W, Thiboutot D, Zouboulis CC: Cutaneous androgen metabolism: Basic research and clinical perspectives. J Invest Dermatol 119:992, 2002
165. Wilt TJ et al: Five-alpha-reductase inhibitors for prostate cancer prevention. Cochrane Database Syst Rev 16: CD007091, 2008
166. Price VH et al: Lack of efficacy of
finasteride in postmenopausal women with androgenetic alopecia.
J Am Acad Dermatol 43:768, 2000
167. Thiboutot D: Acne: Hormonal concepts and therapy. Clin Dermatol 22:419, 2004
168. Kojima M et al: Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402:656, 1999
169. Takaya K et al: Ghrelin strongly stimulates growth hormone release in humans. J Clin Endocrinol Metab 85:4908, 2000
170. Alexander L et al: Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxf) 12:71, 1980
171. Melmed S: Acromegaly. N Engl J Med 322:966, 1990
172. Stratakis CA et al: Carney complex, a familial multiple neoplasia and lentiginosis syndrome. Analysis of 11 kindreds and linkage to the short arm of chromosome 2.J Clin Invest 97:699, 1996
173. Nabarro JD: Acromegaly. Clin Endocrinol (Oxf) 26:481, 1987
174. Melmed S: Medical progress: Acromegaly. N Engl J Med 355:2558, 2006
175. Melmed S et al: Guidelines for acromegaly management. J Clin Endocrinol Metab 87:4054, 2002
176. Molitch ME et al: Evaluation and treatment of adult growth hormone deficiency: N endocrine society clinical practice guideline. J Clin Endocrinol Metab 91:1621, 2006